222 related articles for article (PubMed ID: 1353658)
1. Sulfasalazine desensitization in children and adolescents with chronic inflammatory bowel disease.
Tolia V
Am J Gastroenterol; 1992 Aug; 87(8):1029-32. PubMed ID: 1353658
[TBL] [Abstract][Full Text] [Related]
2. Desensitization to sulfasalazine.
Hessemer CA; Schinagl EF
Am J Gastroenterol; 1993 Mar; 88(3):460-1, 462. PubMed ID: 8094941
[No Abstract] [Full Text] [Related]
3. Desensitization to sulfasalazine after hypersensitivity reactions in patients with inflammatory bowel disease.
Korelitz BI; Present DH; Rubin PH; Fochios SE
J Clin Gastroenterol; 1984 Feb; 6(1):27-31. PubMed ID: 6142067
[TBL] [Abstract][Full Text] [Related]
4. The safety of sulfasalazine: the gastroenterologists' experience.
Sachar DB
J Rheumatol Suppl; 1988 Sep; 16():14-6. PubMed ID: 2903923
[TBL] [Abstract][Full Text] [Related]
5. Adverse effects of sulfasalazine and treatment of ulcerative colitis with mesalazine.
Nakajima H; Munakata A; Yoshida Y
J Gastroenterol; 1995 Nov; 30 Suppl 8():115-7. PubMed ID: 8563870
[TBL] [Abstract][Full Text] [Related]
6. Treatment of ulcerative colitis with oral 5-aminosalicylic acid including patients with adverse reactions to sulfasalazine.
Habal FM; Greenberg GR
Am J Gastroenterol; 1988 Jan; 83(1):15-9. PubMed ID: 2892391
[TBL] [Abstract][Full Text] [Related]
7. Inflammatory bowel diseases, 5-aminosalicylic acid and sulfasalazine treatment and risk of acute pancreatitis: a population-based case-control study.
Munk EM; Pedersen L; Floyd A; Nørgård B; Rasmussen HH; Sørensen HT
Am J Gastroenterol; 2004 May; 99(5):884-8. PubMed ID: 15128355
[TBL] [Abstract][Full Text] [Related]
8. The short- and long-term safety of 5-aminosalicylate products in the treatment of ulcerative colitis.
Baker DE; Kane S
Rev Gastroenterol Disord; 2004; 4(2):86-91. PubMed ID: 15185719
[TBL] [Abstract][Full Text] [Related]
9. Medical therapy for ulcerative colitis in childhood.
Ament ME; Vargas JH
Semin Pediatr Surg; 1994 Feb; 3(1):28-32. PubMed ID: 7914811
[TBL] [Abstract][Full Text] [Related]
10. Inflammatory bowel disease.
Van Rosendaal GM
CMAJ; 1989 Jul; 141(2):113-23; discussion 123-4. PubMed ID: 2568163
[TBL] [Abstract][Full Text] [Related]
11. 5-Aminosalicylic acid derivatives. Clinical and pharmaceutical evaluation.
Christensen LA; Jacobsen BA
Neth J Med; 1989 Jun; 35 Suppl 1():S3-10. PubMed ID: 2702310
[TBL] [Abstract][Full Text] [Related]
12. [Salicylic derivatives in the clinical treatment of inflammatory bowel disease: new perspectives].
Damião AO; Sipahi AM
Rev Hosp Clin Fac Med Sao Paulo; 1989; 44(5):271-8. PubMed ID: 2576896
[TBL] [Abstract][Full Text] [Related]
13. Oral desensitization to 5-aminosalicylic acid medications.
Stelzle RC; Squire EN
Ann Allergy Asthma Immunol; 1999 Jul; 83(1):23-4. PubMed ID: 10437811
[TBL] [Abstract][Full Text] [Related]
14. Adverse effects with oral 5-aminosalicyclic acid.
Fardy JM; Lloyd DA; Reynolds RP
J Clin Gastroenterol; 1988 Dec; 10(6):635-7. PubMed ID: 2906645
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. International Study Group.
Rutgeerts P
Aliment Pharmacol Ther; 1989 Apr; 3(2):183-91. PubMed ID: 2577483
[TBL] [Abstract][Full Text] [Related]
16. Renal tubular damage: an extraintestinal manifestation of chronic inflammatory bowel disease.
Kreisel W; Wolf LM; Grotz W; Grieshaber M
Eur J Gastroenterol Hepatol; 1996 May; 8(5):461-8. PubMed ID: 8804875
[TBL] [Abstract][Full Text] [Related]
17. [Chronic inflammatory intestinal disease and nephritis].
Behrens R; Ruder H
Klin Padiatr; 1992; 204(1):61-4. PubMed ID: 1346814
[TBL] [Abstract][Full Text] [Related]
18. The state of the art in the management of inflammatory bowel disease.
Hanauer SB; Present DH
Rev Gastroenterol Disord; 2003; 3(2):81-92. PubMed ID: 12776005
[TBL] [Abstract][Full Text] [Related]
19. [Hypersensitivity to 5-aminosalicylic acid. Value of desensitization by oral route].
Lachaux A; Le Gall C; Loras-Duclaux I; Aboufadel A; Hermier M
Arch Pediatr; 1997 Feb; 4(2):144-6. PubMed ID: 9097825
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic therapy for inflammatory bowel disease.
Hirschfeld S; Clearfield HR
Am Fam Physician; 1995 Jun; 51(8):1971-5. PubMed ID: 7762487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
